F.D.A. Approves 2 Sickle Cell Treatments, One Using CRISPR Gene Editingnews2023-12-09T02:22:13+00:00December 9th, 2023|The New York Times|
New Sickle Cell Therapies Will Be Out of Reach Where They Are Needed Mostnews2023-12-08T22:46:17+00:00December 8th, 2023|The New York Times|
Sickle-Cell Treatment Created With Gene Editing Wins U.K. Approvalnews2023-11-16T22:23:56+00:00November 16th, 2023|The New York Times|
Panel Tells F.D.A. That CRISPR Sickle Cell Cure Is Safe Enough for Patientsnews2023-10-31T21:21:11+00:00October 31st, 2023|The New York Times|
F.D.A. Experts Will Vote on Safety of a Cure for Sickle Cell Diseasenews2023-10-30T20:19:43+00:00October 30th, 2023|The New York Times|
Suddenly, It Looks Like We’re in a Golden Age for Medicinenews2023-06-23T15:29:07+00:00June 23rd, 2023|The New York Times|
A Dilemma for Governments: How to Pay for Million-Dollar Therapiesnews2023-01-25T00:27:17+00:00January 25th, 2023|The New York Times|
Alzheimer’s APOE4 Genetic Risk Targeted in Promising Trialnews2022-12-02T21:55:07+00:00December 2nd, 2022|The New York Times|
Gene Treatment for Rare Epilepsy Causes Brain Side Effect in 2 Childrennews2022-10-26T18:19:16+00:00October 26th, 2022|The New York Times|
Cáncer sin quimioterapia: una revolución silenciosanews2021-10-04T17:53:12+00:00October 4th, 2021|The New York Times|
